SCHEMBL323769

SCHEMBL323769

COCCOC(=O)N1C=Cc2ccccc2C1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
HDAC3 O15379 1/20 0.41
NAMPT P43490 7/20 0.37
HSD17B3 P37058 1/20 0.35
P2RX4 Q99571 2/20 0.34
KDM4E B2RXH2 3/20 0.33
PARP1 P09874 2/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP13 P45452 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 2/20 0.32
GAA P10253 1/20 0.32
PARP2 Q9UGN5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5721697 0.88 ALDH1A1 (0.41) TSHRHDAC3NAMPTHSD17B3P2RX4
SCHEMBL15056964 0.86 HDAC3 (0.41) TSHRHDAC3NAMPTHSD17B3KDM4E
SCHEMBL29493251 0.86 HDAC3 (0.41) TSHRHDAC3NAMPTHSD17B3KDM4E
SCHEMBL323621 0.85 P2RX4 (0.44) TSHRHDAC3NAMPTP2RX4MMP1
SCHEMBL324190 0.85 BCHE (0.44) TSHRHDAC3NAMPTKDM4EALDH1A1
SCHEMBL15056529 0.84 P2RX4 (0.39) HDAC3NAMPTHSD17B3P2RX4HTT
SCHEMBL15056629 0.84 HDAC3 (0.39) HDAC3HSD17B3P2RX4ALDH1A1
SCHEMBL15056981 0.84 HDAC3 (0.35) HDAC3NAMPTHSD17B3P2RX4
SCHEMBL15056675 0.83 HDAC3 (0.36) HDAC3NAMPTHSD17B3P2RX4ALDH1A1
SCHEMBL3628702 0.83 P2RX4 (0.46) HDAC3NAMPTHSD17B3P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 WO disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 TSHR 262/4885HDAC3 1468/4885NAMPT 1639/4885
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 TSHR 317/4885HDAC3 2109/4885NAMPT 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.